April 1, 2026Northern Health is at the forefront of clinical innovation, becoming a key site in a global first-in-human trial investigating a novel absorbable stent designed to transform the treatment of peripheral vascular disease (PVD).
Led by the Vascular Surgery team, Northern Health is participating in a global trial of a new device, which aims to improve outcomes for patients living with PVD, a condition where blocked arteries in the legs can lead to pain, ulcers and, in severe cases, amputation.
“There are millions of people in the world living with one or no legs because of vascular disease,” said Dr Lew Schwartz, vascular surgeon at Lutheran General Hospital, Illinois and Chief Medical Officer at Efemoral Medical, the company behind the device.
While current treatments can open arteries, they are often not durable, with many patients requiring repeat procedures. This new, purpose-built stent is designed specifically for the arteries of the thigh and offers a different approach.
“This is the first trial of an absorbable stent for this part of the body,” Dr Schwartz said.
“Unlike traditional metal stents, this device supports the artery and then dissolves over time. The goal is to treat the vessel effectively without leaving anything permanent behind.”
Northern Health was selected as a trial site based on its strong clinical expertise and research capability.
“As an international sponsor, we can choose sites anywhere in the world, and here we are in Epping,” Dr Schwartz said.
The trial is led locally by Dr Shrikkanth (Raj) Rangarajan, Vascular Surgeon at Northern Health, alongside Dr Vikram Iyer and Dr David Goh, supported by a dedicated multidisciplinary team.
“For us, this reflects who we are,” Dr Rangarajan said.
“Northern Health has a strong research track record, and this trial demonstrates our ability to contribute to world-leading innovation.”
“Today, we performed the 50th case globally. That is a significant milestone and a testament to the entire team.”
At its core, the trial is focused on improving long-term patient outcomes.
“It is not just about opening an artery,” Dr Rangarajan said.
“Patients want treatments that last. This is about achieving durable results and reducing the need for repeat procedures.”
This marks Northern Health’s third first-in-human vascular trial, highlighting its continued investment in research, governance and innovation.
“It is actually an honour to be chosen to run a first-in-human trial,” Dr Schwartz said.
As the trial progresses, its potential impact is significant, both locally and globally.
“If successful, this could change the way we treat vascular disease,” Dr Rangarajan said.
“The goal is simple. Treatments that are effective, durable, and reduce the need for further intervention.”
For Northern Health, it represents another step forward in delivering world-class care to the community, ensuring patients in Melbourne’s north have access to the latest advancements in medical treatment.
And for patients, it offers something equally important: a future with better outcomes, fewer procedures, and renewed confidence in their care.
Vascular Surgery Team
Featured Image: Dr Shrikkanth (Raj) Rangarajan and Dr Lew Schwartz
